Tofacitinib . citrate | 10-047

Tofacitinib . citrate | 10-047 | Gentaur UK, US & Europe Distribution

BNR: Chemical

Predicted Molecular Weight: 312.4 . 192.1

Physical State: Lyophilized

Storage Condition: Short Term Storage: +4C. Long Term Storage: -20C. Handling Advice: Keep cool and dry. Protect from moisture and oxygen. Use/Stability: Stable for at least 2 years after receipt when stored at -20C.

Alternate Name: CP-690550; Xeljanz; Tasocitinib

Background: Potent cell permeable JAK3 inhibitor (IC50 = 1nM) . Shows also JAK-1 inhibitory activity. Immunosuppressive and anti-inflammatory agent. Inhibits signaling through heterodimeric receptors associated with JAK3, JAK1, or both of them, with functional selectivity over JAK2-paired receptors. Blocks downstream STAT signaling, resulting in potent inhibition of several cytokines, including interleukins 2, 4, 7, 9, 15 and 21, which are integral to lymphocyte activation, function and proliferation. Investigated for several autoimmune disorders including, rheumatoid arthritis and psoriasis. Potent and selective inhibitor of HIV-1 replication and virus reactivation in vitro. It is investigated against the spread of the SARS-CoV-2 (COVID-19) . PRK1 inhibitor.

Disclaimer: This product is for research use only.

Purity: greater than or equal to 98% (HPLC)

Formula: C16H20N6O . C6H8O7

Source: N/A

Solubility: Soluble in ethanol (10mg/ml), DMSO (15mg/ml) or DMF (20mg/ml) .

InChi Key: SYIKUFDOYJFGBQ-YLAFAASESA-N

Smiles: OC (CC (O) =O) (CC (O) =O) C (O) =O.O=C (CC#N) N1C[C@@H] ([C@H] (C) CC1) N (C) C2=NC=NC3=C2C=CN3

RTECS: N/A

Identity: Determined by 1H-NMR.

Merck Index: N/A